Target intelligence / Profile preview

Coli surface antigen 5 (CS5)

Target
CS5
Molecular classification
Bacterial outer membrane protein, Adhesin, Fimbrial protein, Other
01

Overview

Coli surface antigen 5 (CS5), also known as CS5 fimbrial antigen, is a plasmid-encoded, helical fibrillar adhesin expressed on the surface of enterotoxigenic Escherichia coli (ETEC). It is a key colonization factor that mediates the attachment of ETEC to host small intestinal epithelial cells, a critical initial step in the pathogenesis of ETEC-mediated diarrheal disease. The CS5 operon consists of six genes (csfA-F) encoding the major subunit CsfA, minor subunit CsfD, outer membrane usher CsfC, chaperones CsfB and CsfF, and length regulator CsfE. Expression of CS5 is highly regulated by host environmental cues, particularly requiring the presence of bile salts such as sodium glycocholate in the gut lumen.

In clinical development, CS5 is a major target for multivalent ETEC vaccines aimed at preventing traveler's diarrhea and childhood diarrhea in endemic regions. Vaccines such as ETVAX (an oral inactivated whole-cell vaccine) and ACE527 (a live attenuated vaccine) incorporate CS5-expressing strains or recombinant CS5 antigens to elicit protective mucosal IgA and systemic IgG antibody responses. These antibodies neutralize the adhesin, preventing bacterial colonization and subsequent enterotoxin-mediated fluid secretion. Therapeutic challenges include the high antigenic diversity of ETEC strains and the need to maintain the structural integrity of the fimbriae during vaccine formulation and inactivation.

Other names
CS5 fimbrial antigenCS5 antigenCS5 fimbriaeColi surface-associated antigen CS5Coli surface-associated antigen 5CsfACS5 pilinCS5 major fimbrial subunit
02

Mechanism of action

Active immunization to induce mucosal IgA and systemic IgG antibodies that bind to the CS5 fimbrial antigen, thereby blocking bacterial adhesion and colonization of the small intestinal epithelium by enterotoxigenic Escherichia coli (ETEC).

03

Biological functions

Bacterial adhesionCell aggregationHost colonizationOther
04

Disease associations

Infection
05

Safety considerations

Antigenic variation and heterogeneity among ETEC strainsRequirement of bile salts for optimal expression of CS5 in vivo, which can affect vaccine immunogenicity and challenge model consistencyPotential for oral vaccines to cause mild gastrointestinal side effects such as transient diarrhea, abdominal cramping, or nauseaInactivation methods can affect the structural integrity and immunogenicity of fimbrial antigens
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

CS5-specific secretory IgA (sIgA)CS5-specific serum IgACS5-specific serum IgGCS5-specific CD4+ T cell response

Beyond the preview

Go deeper on Coli surface antigen 5 (CS5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coli surface antigen 5 (CS5).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call